Novo owner backs Swiss biotech company Asceneuron in $100 million round
Swiss biotech company Asceneuron said Tuesday it has raised $100 million from investors including controlling shareholder Wegovy maker Novo Nordisk to fund clinical development of its drug to treat Alzheimer’s disease.
BELIEBTE BEITRÄGE
UK sets new climate target for 2035
November 13, 2024
Children go back to school after Valencia floods
November 13, 2024
Researchers document huge decline in African elephants
November 13, 2024
Mission: Impossible 8 title revealed
November 13, 2024
LIVEÜBERTRAGUNG